INTRODUCTION

Persistent nasal airway obstruction (NAO) due to midvault soft tissue collapse in patients following rhinoplasty or nasal surgery is a clinical challenge for surgeons. An absorbable lateral nasal wall implant is one option available to help treat midvault soft tissue collapse and to improve NAO symptoms. Previous studies have not investigated its use in complex revision functional rhinoplasty with respect to patient-reported outcomes. Data were collected on all patients with a history of previous nasal procedures who underwent Latera implant placement in conjunction with functional rhinoplasty from January to December 2018. The Nasal Obstructive Symptom Evaluation and Visual Analogue Scale were used to evaluate functional outcomes. Eight implants were placed in 6 revision functional rhinoplasty patients with midvault collapse. All patients responded to the survey. Mean follow-up was 16 ± 4 months. There were no implant-related adverse events. Mean Nasal Obstructive Symptom Evaluation score was 33 ± 33, and mean Visual Analogue Scale score was 20 ± 9. In total, 1 patient reported complete resolution of NAO, whereas 2 patients reported mild, 1 reported moderate, 1 reported severe, and 1 reported extreme symptoms. Four of the 6 patients reported nasal obstruction improvement, with all reporting improvement in midvault soft tissue collapse. Apart from being used in nasal valve collapse treatment, a lateral nasal wall implant is a potentially useful solution that may help surgeons improve patients’ NAO symptoms in complex functional rhinoplasty cases. However, in certain cases, a patient’s nasal obstructive symptoms may continue to be multifactorial. (Plast Reconstr Surg Glob Open 2020;8:e2887; doi: 10.1097/GOX.0000000000002887; Published online 17 June 2020.)

METHODS

After Institutional Review Board approval at Beth Israel Deaconess Medical Center (Protocol: 2019P000651), data were collected on adult patients with a history of multiple nasal procedures who underwent revision functional rhinoplasty with the Latera implant to improve NAO symptoms from soft tissue midvault collapse, an area not being treated by standard nasal obstruction techniques.
centered upon the exact area of symptomatic collapse, and the preexisting scar did not preclude its placement.

The Nasal Obstructive Symptom Evaluation (NOSE) and Visual Analogue Scale (VAS) were used to evaluate functional outcomes. The NOSE is a validated instrument widely used to evaluate functional outcomes, with severity scores ranging from 0 (no nasal obstruction) to 100 (worst possible nasal obstruction). This was further classified into mild (5–25 points), moderate (30–50 points), severe (55–75 points), and extreme (80–100 points). A VAS score from 0 (no difficulty) to 100 (maximum imaginable difficulty) was used to capture patients' perception of their ability to breathe through the nose. Data collection also included demographic information, nasal medical history, and previous operations. Patients were contacted by phone and were offered to complete the survey either via phone or e-mail.

RESULTS

From January to December 2018, 8 Latera implants were placed in 6 revision functional rhinoplasty patients. Of these patients, 4 never smoked, 2 previously smoked, 5 presented with persistent nasal obstruction symptoms following previous nasal obstructive procedures, and 1 required reconstruction following Mohs resection with subsequent nasal wall collapse. Mean age ± SD was 50 ± 14 years. Mean follow up was 16 ± 4 months. Nasal medical history and previous operations are summarized in Table 1.

No patients had implant-related complications (ie, extrusion, infection, pain). All patients responded to the survey, with NOSE and VAS scores listed in Figure 3. Mean NOSE score was 33 ± 33, and VAS score was 20 ± 9. One patient reported complete resolution of NAO, and 2 patients reported mild symptoms (NOSE: 5 and 15, VAS: 3 and 25, respectively). Two underwent revision functional rhinoplasty with bilateral Latera implant placement, with 2 reporting moderate symptoms (NOSE: 40, VAS: 25), 1 reporting severe symptoms (NOSE: 55, VAS: 29), and another reporting extreme symptoms (NOSE: 85, VAS: 20).

In total, 4 of 6 patients reported improvement of nasal obstruction at follow up over 1 year, with all patients reporting improvement of midvault soft tissue collapse, the original indication for surgery, on the symptomatic side.

DISCUSSION

In this case series, our findings of NOSE and VAS scores were similar to those in previously published studies. Two studies with inclusion criteria of failed medical management of at least 4 weeks evaluated functional outcomes following NVC treatment with the Latera implant under local anaesthesia in clinic-based settings. Both of them demonstrated significant improvement of NOSE and VAS scores at 3 months and at 12 months. San Nicoló et al published 1- and 2-year evaluations of NVC treatment with the Latera implant, reporting significant improvement of NAO symptoms and improvement of NOSE scores.

As one of the most technically challenging operations, rhinoplasty may have revision rates range from 5% to 15%, with numerous patients requiring revisions for postoperative NAO symptoms and compromised breathing.
to 70% of these revision patients report breathing as the main complaint, whether from residual septal deviation, nasal valve stenosis, or alar collapse. A satisfactory outcome may be especially difficult to achieve given surgical alteration or potential weakening of the nasal soft tissue, cartilage system, and prior use of standard options (septoplasty, spreader grafting, turbinate reduction). The senior author has not found consistent success with conventional cartilage (rib, septum, ear) grafting of the midvault for nasal soft tissue collapse for nasal obstruction; weighing the morbidity of a remote donor site, we sought an alternative procedure. From the findings of our study, the absorbable Latera implant may be a useful adjunct due to the support it provides the upper and lower lateral cartilages of the nose, separate from the internal nasal valve and internal anatomy of the nose. The senior author also notes that patients who have had multiple reduction rhinoplasties may not have enough cartilage and placement of Latera implant could be challenging.

The main limitations of this study are sample size and missing baseline NOSE and VAS scores to compare with postoperative follow-up results. Additionally, instruments used in this study are subjective, and patient variability in reporting is another important consideration. Moreover, the true impact of the Latera implant on nasal obstruction improvement may be difficult to isolate given that patients had concurrent procedures.

CONCLUSIONS

The Latera implant is potentially useful in helping surgeons improve certain patients’ NAO symptoms due to midvault soft tissue collapse. Apart from use in NVC treatment, it may be considered for use in complex functional rhinoplasty cases given the relatively satisfactory outcomes. However, nasal obstruction is still multifactorial from the standpoint of the nasal lining, environmental causes, and other etiologies.

Samuel Lin, MD, MBA
Division of Plastic Surgery
Department of Surgery
Beth Israel Deaconess Medical Center
Harvard Medical School
110 Francis Street Suite 5A
Boston, MA
E-mail: sjlin@bidmc.harvard.edu
REFERENCES

1. Rhee JS, Book DT, Burzynski M, et al. Quality of life assessment in nasal airway obstruction. *Laryngoscope*. 2003;113:1118–1122.

2. Mohan S, Fuller JC, Ford SF, et al. Diagnostic and therapeutic management of nasal airway obstruction: advances in diagnosis and treatment. *JAMA Facial Plast Surg*. 2018;20:409–418.

3. Clark DW, Del Signore AG, Raithatha R, et al. Nasal airway obstruction: prevalence and anatomic contributors. *Ear Nose Throat J*. 2018;97:173–176.

4. Kandathil CK, Spataro EA, Laimi K, et al. Repair of the lateral nasal wall in nasal airway obstruction: a systematic review and meta-analysis. *JAMA Facial Plast Surg*. 2018;20:307–313.

5. Sheen JH. Spreader graft: a method of reconstructing the roof of the middle nasal vault following rhinoplasty. *Plast Reconstr Surg*. 1984;73:230–239.

6. Lavinsky-Wolff M, Camargo HI, Jr, Barone CR, et al. Effect of turbinate surgery in rhinoseptoplasty on quality-of-life and acoustic rhinometry outcomes: a randomized clinical trial. *Laryngoscope*. 2013;123:82–89.

7. Toriumi DM, Josen J, Weinberger M, et al. Use of alar batten grafts for correction of nasal valve collapse. *Arch Otolaryngol Head Neck Surg*. 1997;123:802–808.

8. San Nicolò M, Stelter K, Sadick H, et al. A 2-year follow-up study of an absorbable implant to treat nasal valve collapse. *Facial Plast Surg*. 2018;34:545–550.

9. San Nicolò M, Stelter K, Sadick H, et al. Absorbable implant to treat nasal valve collapse. *Facial Plast Surg*. 2017;33:233–240.

10. Stolovitzky P, Senior B, Ow RA, et al. Assessment of bioabsorbable implant treatment for nasal valve collapse compared to a sham group: a randomized control trial. *Int Forum Allergy Rhinol*. 2019;9:850–856.

11. Siddle DM, Stolovitzky P, Ow RA, et al. Twelve-month outcomes of a bioabsorbable implant for in-office treatment of dynamic nasal valve collapse. *Laryngoscope*. 2020;130:1132–1137.

12. Rhee JS, Sullivan CD, Frank DO, et al. A systematic review of patient-reported nasal obstruction scores: defining normative and symptomatic ranges in surgical patients. *JAMA Facial Plast Surg*. 2014;16:219–225; quiz 232.

13. Stewart MG, Witsell DL, Smith TL, et al. Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. *Otolaryngol Head Neck Surg*. 2004;130:157–163.

14. Floyd EM, Ho S, Patel P, et al. Systematic review and meta-analysis of studies evaluating functional rhinoplasty outcomes with the NOSE score. *Otolaryngol Head Neck Surg*. 2017;156:809–815.

15. Lipan MJ, Most SP. Development of a severity classification system for subjective nasal obstruction. *JAMA Facial Plast Surg*. 2013;15:358–361.

16. Rohrich RJ, Ahmad J. Rhinoplasty. *Plast Reconstr Surg*. 2011;128:49e–73e.

17. Tanna N, Nguyen KT, Ghavami A, et al. Evidence-based medicine: current practices in rhinoplasty. *Plast Reconstr Surg*. 2018;141:137e–151e.

18. Neaman KC, Boettcher AK, Do VH, et al. Cosmetic rhinoplasty: revision rates revisited. *Aesthet Surg J*. 2013;33:31–37.

19. Bracaglia R, Fortunato R, Gentileschi S. Secondary rhinoplasty. *Aesthetic Plast Surg*. 2005;29:230–239.

20. Foda HM. Rhinoplasty for the multiply revised nose. *Am J Otolaryngol*. 2005;26:28–34.